Home › Funds › Ikarian Capital, LLC › MRNA
Ikarian Capital, LLC position in MRNA
MODERNA INC · Health Care
Ikarian Capital, LLC reported holding 400,000 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$77.0M, representing 11.31% of its reported portfolio and ranking #1 among its reported holdings. Ikarian Capital, LLC has disclosed MRNA holdings in 5 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's MRNA position evolved
Ikarian Capital, LLC first disclosed a stake in MRNA in Q3 2023 at 2,443 shares (US$25.2M). The position peaked in Q3 2026 at 400,000 shares, worth US$77.0M. Across 5 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 400,000 shares valued at US$77.0M. Notable position changes include a 905% increase in Q4 2023 (shares rose 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.44K | $25.23M | New |
| Q4 2023 | 24.55K | $2.44M | Add |
| Q4 2024 | 100.00K | $4.16M | New |
| Q2 2026 | 400.00K | $28.01M | New |
| Q3 2026 | 400.00K | $77.03M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 47 other funds we track also report a position in MRNA — the largest reported positions include Fidelity Management & Research (FMR) (US$11.35B), Capital World Investors (US$4.36B), Baillie Gifford & Co (US$2.20B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Fidelity Management & Research (FMR) 58.96M sh · $11.35B · Q3 2026
- Capital World Investors 22.64M sh · $4.36B · Q3 2026
- Baillie Gifford & Co 11.44M sh · $2.20B · Q3 2026
- Theleme Partners LLP 6.66M sh · $1.28B · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $892.01M · Q3 2026
- IMC-Chicago, LLC 3.07M sh · $590.92M · Q3 2026
- SUSQUEHANNA INTERNATIONAL GROUP, LLP 2.42M sh · $466.58M · Q3 2026
- Merck & Co., Inc. 2.31M sh · $444.49M · Q3 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- a16z Perennial Management, L.P. 1.52M sh · $292.57M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.40M sh · $269.60M · Q3 2026
- BAMCO INC /NY/ 1.39M sh · $267.88M · Q3 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held MRNA?
Ikarian Capital, LLC has disclosed MRNA holdings in 5 of the last 13 reported quarters, going back to Q3 2023.
What is Ikarian Capital, LLC's current position in MRNA?
As of Q3 2026, Ikarian Capital, LLC holds 400.00K shares of MRNA (MODERNA INC), valued at $77.03M, representing 11.31% of its reported portfolio and ranking #1.
Has Ikarian Capital, LLC been buying or selling MRNA?
In the latest 13F filing (Q3 2026), Ikarian Capital, LLC held unchanged its position in MRNA. The position peaked in Q3 2026 at 400.00K shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Fidelity Management & Research (FMR), Capital World Investors, Baillie Gifford & Co, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.